MK-677 (Ibutamoren) and Imaging Contrast Dye: What Patients Need to Know

What Is MK-677 and How Does It Work?

MK-677 (ibutamoren) is an orally active, non-peptide agonist of the ghrelin receptor (GHSR-1a). It stimulates pulsatile growth hormone (GH) secretion from the pituitary without suppressing the hypothalamic-pituitary axis, unlike exogenous GH injections.

Mechanism of Action

By mimicking ghrelin, MK-677 amplifies endogenous GH pulses and raises serum insulin-like growth factor 1 (IGF-1) in a dose-dependent fashion. In a 2-year randomized trial by Nass et al. (N=65 elderly adults), 25 mg daily raised IGF-1 by approximately 40% above baseline and increased GH pulse amplitude without suppressing cortisol or thyroid axes at that dose [1].

Downstream Physiological Effects Relevant to Contrast Imaging

These downstream GH/IGF-1 changes matter for contrast imaging for three reasons:

1. Fluid and sodium retention. GH and IGF-1 both activate renal tubular sodium reabsorption. In phase II trials, MK-677 produced peripheral edema in roughly 9 to 14% of participants at the 25 mg dose [2]. Edematous patients already carry an expanded extracellular fluid volume, which changes the pharmacokinetics of renally cleared contrast media.

2. Glucose and insulin effects. MK-677 produces a consistent, modest rise in fasting blood glucose, averaging 0.3 mmol/L in the Nass trial [1]. Iodinated contrast agents transiently impair insulin secretion and raise plasma osmolality. The combination may push glucose higher than either agent alone.

3. GFR and renal hemodynamics. IGF-1 is a renal vasodilator and glomerular growth factor. Short-term IGF-1 elevation raises GFR slightly, but chronic fluid retention and subclinical volume overload can have the opposite effect in susceptible individuals. Baseline renal function therefore deserves screening before contrast exposure in any MK-677 user.

Iodinated Contrast Agents: CT, Angiography, and Contrast-Induced Nephropathy Risk

Iodinated contrast media (ICM) used in CT scans and angiograms are nephrotoxic at sufficient concentrations, particularly in patients with pre-existing chronic kidney disease (CKD), diabetes, or hemodynamic compromise [3].

What Contrast-Induced Nephropathy Means in Practice

Contrast-induced nephropathy (CIN) is defined as an absolute rise in serum creatinine of 0.5 mg/dL or a relative rise of 25% within 48 to 72 hours of contrast exposure [3]. In an unselected outpatient population, CIN incidence is under 2%. In patients with an estimated GFR (eGFR) <45 mL/min/1.73 m², it climbs to 12 to 15% [4].

MK-677 users rarely have overtly impaired kidneys, given the drug's typical user demographic (young to middle-aged adults seeking body composition or anti-aging effects). But MK-677's fluid-retaining effect and the possibility of subclinical volume shifts mean baseline eGFR confirmation is sensible before any contrast study.

Osmolality and Glucose Loading

High-osmolality iodinated contrast agents (e.g., diatrizoate, osmolality 1,400 to 1,800 mOsm/kg) impose an osmotic load that can transiently raise blood glucose in pre-diabetic individuals [5]. Low-osmolality agents (iohexol, iopamidol, osmolality 290 to 860 mOsm/kg) carry a much smaller glycemic signal and are standard of care at most centers. Regardless, patients with MK-677-associated fasting hyperglycemia (common at the 25 mg dose) should have glucose checked before and after contrast administration.

Pre-Imaging Steps for MK-677 Users Receiving Iodinated Contrast

• Obtain a baseline comprehensive metabolic panel, including creatinine and eGFR, within 3 months of the planned scan (or within 30 days if clinically indicated).
• Ensure adequate hydration before and after the procedure. The ACR Manual on Contrast Media recommends IV 0.9% normal saline or sodium bicarbonate infusion in patients with eGFR <45 [6].
• Inform the radiologist about MK-677 use so they can document it in the contrast screening form.
• Consider whether a 24 to 48 h hold on MK-677 is warranted. No published guideline mandates this, but temporarily reducing the fluid-retaining stimulus before a procedure with renal implications is a defensible precaution.

Gadolinium Contrast Agents: MRI and Specific Risks

Gadolinium-based contrast agents (GBCAs) used in MRI carry a different risk profile than iodinated agents. The primary concern is nephrogenic systemic fibrosis (NSF), a rare but serious fibrosing disorder linked to gadolinium deposition in patients with severely reduced GFR [7].

NSF Risk Stratification

The ACR categorizes GBCAs into Group I (higher NSF risk: gadodiamide, gadopentetate dimeglumine), Group II (intermediate), and Group III (lowest risk: gadobutrol, gadoteridol, gadoterate meglumine) [6]. Current ACR guidance restricts Group I agents in patients with eGFR <30 mL/min/1.73 m² and advises caution below eGFR 45 for any GBCA.

MK-677 users with significant peripheral edema should be asked whether the edema is new or worsening, since progressive fluid retention may signal declining renal reserve worth confirming with labs before gadolinium exposure.

Gadolinium Retention Beyond the Kidney

Emerging data show gadolinium deposits in brain tissue (particularly the dentate nucleus and globus pallidus) even in patients with normal renal function, primarily with linear (non-macrocyclic) agents [8]. Whether MK-677-driven IGF-1 elevation affects blood-brain barrier permeability or glymphatic clearance of gadolinium is unknown. This is a gap in the literature, not a proven hazard, but it supports preferential use of macrocyclic agents in MK-677 users when the radiologist has a choice.

A Practical Renal Screening Framework for MK-677 Users Before Contrast MRI

| Patient Profile | Recommended Action Before GBCA | |---|---| | No edema, eGFR >60, no diabetes | Standard ACR pre-screening; no MK-677 hold required | | Peripheral edema, eGFR 45 to 60 | Check creatinine within 30 days; discuss 24 to 48 h MK-677 hold; prefer macrocyclic GBCA | | Edema, eGFR <45 | Nephrology consult before GBCA; hold MK-677; use Group III macrocyclic agent only | | eGFR <30 | Avoid Group I/II GBCAs; nephrology co-management required |

MK-677 and Alcohol: A Separate but Common Interaction Question

Patients on MK-677 frequently ask about alcohol. Alcohol is not a contrast agent, but the question appears in the secondary query list and deserves a clear answer.

How Alcohol Suppresses GH Secretion

Acute alcohol ingestion suppresses hypothalamic GH-releasing hormone (GHRH) and blunts pituitary GH pulsatility. A 1993 study by Tentler et al. Demonstrated that blood alcohol levels of 80 to 100 mg/dL reduced nocturnal GH secretion by approximately 75% in healthy men [9]. MK-677's mechanism depends on amplifying exactly these GH pulses. Consuming alcohol on the same evening as MK-677 likely offsets a substantial portion of the drug's GH-stimulating effect.

Hepatic and Metabolic Overlap

Both alcohol and MK-677 affect hepatic IGF-1 synthesis, though in opposite directions. Chronic alcohol use suppresses hepatic IGF-1 production; MK-677 raises it. In a patient consuming alcohol regularly, the net IGF-1 response to MK-677 may be attenuated compared to published trial data obtained in abstinent or light-drinking participants [1].

MK-677 also raises fasting insulin levels modestly, as noted in the Nass trial [1]. Alcohol causes erratic glycemic swings (hypoglycemia with fasting, hyperglycemia after carbohydrate-rich drinking). Together, these effects complicate blood glucose management, particularly in users who have pre-existing insulin resistance.

Practical Guidance on Alcohol and MK-677

Avoiding alcohol on the night of MK-677 dosing preserves the nocturnal GH pulse the drug is designed to augment. Occasional moderate alcohol use (1 to 2 standard drinks on separate days from dosing) is less likely to be clinically significant, but chronic heavy use (over 14 drinks per week) may substantially blunt IGF-1 response and adds hepatotoxic risk in an unregulated supplement context.

General MK-677 Drug Interactions: The Broader Picture

MK-677 is metabolized primarily by CYP3A4 and is a substrate, not a strong inhibitor, of that enzyme. Its interaction profile with pharmaceuticals stems less from CYP competition and more from its pharmacodynamic downstream effects on GH, IGF-1, glucose, and fluid balance.

Insulin and Antidiabetic Agents

MK-677 raises fasting blood glucose and fasting insulin. Patients on insulin or sulfonylureas (glipizide, glyburide, glimepiride) may need dose adjustment to avoid hypoglycemia, since basal insulin levels are already elevated by MK-677's effect on IGF-1-mediated insulin signaling. A 2022 review in the Journal of Clinical Endocrinology and Metabolism noted that GH secretagogues as a class produce insulin resistance at doses yielding supraphysiologic IGF-1 [10].

Corticosteroids

Corticosteroids blunt GH secretion through multiple mechanisms, including increasing somatostatin tone. Patients on prednisone, dexamethasone, or inhaled corticosteroids at high doses may see reduced MK-677 efficacy. The clinical magnitude of this interaction has not been quantified in a dedicated trial.

Thyroid Hormones

GH and IGF-1 promote conversion of T4 to the active T3 via hepatic and peripheral deiodinase activity. MK-677 may therefore increase free T3 slightly and reduce free T4 in euthyroid individuals, a phenomenon observed with exogenous GH therapy [11]. Patients on levothyroxine should have thyroid function checked 6 to 8 weeks after starting MK-677, and again if their dose is adjusted.

Water-Retaining Drugs

Combining MK-677 with other sodium-retaining agents, including fludrocortisone, NSAIDs, or certain antihypertensives that raise aldosterone (e.g., dihydropyridine calcium channel blockers at high doses), may worsen fluid retention and edema. Blood pressure monitoring is warranted in this combination.

Regulatory Status and Why It Matters for Interaction Data

MK-677 is not approved by the FDA for any indication. It is classified as an investigational compound. The FDA has not evaluated its safety in combination with imaging contrast agents, and no label exists to guide contrast-imaging interactions [12].

The most rigorous human data come from trials by Smith et al. (1997, N=32 obese adults; 2-week 25 mg dosing), the Nass et al. NEJM trial (2008, N=65 elderly adults; 2 years of follow-up), and the Copinschi et al. Trial in healthy young adults, all of which were designed to assess GH/IGF-1 efficacy, not drug-drug interactions [1,2,13].

Because MK-677 is sold as a "research chemical" or dietary supplement in many markets, purity, actual dose, and excipient composition are unverified. Impurities could theoretically produce additional interactions with contrast agents or with metabolic pathways. This represents an additional unmeasured risk not present with approved pharmaceuticals.

What to Tell Your Radiologist and Ordering Physician

Disclosure is the single most actionable step. Radiology departments use structured contrast screening questionnaires, but these questionnaires rarely ask about investigational research chemicals or dietary supplements by name.

Patients should state clearly:

• "I am taking MK-677 (ibutamoren), a growth hormone secretagogue, at [dose] mg daily."
• "I have [or have not] noticed peripheral edema or ankle swelling since starting."
• "My last fasting glucose was [value] and my last creatinine/eGFR was [value]."

This information allows the radiologist to select the appropriate contrast agent, confirm renal function labs are current, plan hydration protocols, and document the interaction for clinical records.

The American College of Radiology's 2023 Manual on Contrast Media states: "All medications affecting renal function, blood pressure, or fluid balance should be documented prior to contrast administration, and the ordering physician should be notified of any agent whose interaction with contrast media has not been formally evaluated." [6]

This language directly applies to MK-677.

Monitoring Parameters After Contrast Imaging in MK-677 Users

Post-procedure monitoring for MK-677 users receiving contrast should include:

• Serum creatinine and eGFR at 48 to 72 hours if pre-procedure eGFR was <60 mL/min/1.73 m² or if the patient had visible edema.
• Blood glucose check at 2 to 4 hours post-contrast in patients with MK-677-associated fasting hyperglycemia or pre-diabetes.
• Urine output monitoring for 24 hours; oliguria (<0.5 mL/kg/h) warrants urgent nephrology evaluation.
• Blood pressure at the 48-hour visit, given MK-677's sodium-retaining potential and the volume stress of contrast administration.

If creatinine rises by 0.5 mg/dL or more within 72 hours of contrast exposure, MK-677 should be held and nephrology consulted, per standard CIN management protocols [3].